FDA Drug Approval Summary: Bevacizumab Plus FOLFOX4 as Second-Line Treatment of Colorectal Cancer-Reference-Cited by-同舟云学术

FDA Drug Approval Summary: Bevacizumab Plus FOLFOX4 as Second-Line Treatment of Colorectal Cancer

Published:2007-03-01 Issue:3 Volume:12 Page:356-361
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Cohen Martin H.¹,Gootenberg Joe¹,Keegan Patricia¹,Pazdur Richard¹

Affiliation:

1. Division of Biological Oncology Products, Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA

Abstract

Learning Objectives After completing this course, the reader will be able to: Add bevacizumab (Avastin®) to the FOLFOX4 chemotherapy regimen.Evaluate the contribution of bevacizumab and FOLFOX4 to treatment results.Understand FDA criteria for the analysis of response rate and progression-free survival. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.12-3-356

Reference4 articles.

1. Lessons from phase III clinical trials on anti-VEGF therapy for cancer;Jain;Nat Clin Pract Oncol,2006

2. Clinical translation of angiogenesis inhibitors;Kerbel;Nat Rev Cancer,2002

3. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer;Ferrara;Nat Rev Drug Discov,2004

4. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004

Cited by 163 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A weighted combination of reproducing kernel particle shape functions with cardinal functions of scalable polyharmonic spline radial kernel utilized in Galerkin weak form of a mathematical model related to anti-angiogenic therapy;Communications in Nonlinear Science and Numerical Simulation;2024-08

2. Fabrication of poly (lactic-co-glycolic acid)/mesoporous silica composite nanofibers for controllable co-delivery of 5-fluorouracil and curcumin against HT-29 colon cancer cells;Journal of Materials Science;2024-02

3. Risks of hypertension and thromboembolism in patients receiving bevacizumab with chemotherapy for colorectal cancer: A systematic review and meta‐analysis;Cancer Medicine;2023-12

4. Cancer cell-specific gene disruption of VEGF-A using Cas9;Personalized Medicine Universe;2023-11-30

5. Cutaneous adverse reactions resulting from targeted cancer therapies: histopathologic and clinical findings;Human Pathology;2023-10